Lexeo Therapeutics CLO files Form 4 for tax-related share sale

Rhea-AI Filing Summary

Lexeo Therapeutics (LXEO) Chief Legal Officer Form 4 filing reports a small insider sale tied to tax obligations. On 11/18/2025, the officer sold 549 shares of common stock in a sale to cover taxes due upon the release of restricted stock units. The weighted average sale price was $9.27 per share, based on multiple trades between $9.09 and $9.37.

After this transaction, the officer beneficially owns 68,381 shares of Lexeo Therapeutics common stock, which includes 49,607 restricted stock units. The filing states that detailed trade‑by‑trade pricing information will be provided upon request to the SEC staff, the company, or any security holder.

Insider Trade Summary

Net Seller: 549 shares ($5,089)

Net Sell 1 txn

Insider Robertson Jenny

Role Chief Legal Officer

Sold 549 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	549	$9.27	$5K

Holdings After Transaction: Common Stock — 68,381 shares (Direct)

Footnotes (1)

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs"). This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Includes 49,607 RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robertson Jenny

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		S(1)		549	D	$9.27(2)	68,381(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $9.09 to $9.37. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 49,607 RSUs.

	/s/ Youjin Choi, Attorney-in-Fact	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lexeo Therapeutics (LXEO) disclose in this Form 4 filing?

The filing shows that a Lexeo Therapeutics officer, the Chief Legal Officer, reported the sale of 549 shares of common stock on 11/18/2025 in connection with tax obligations on the release of restricted stock units.

How many Lexeo Therapeutics (LXEO) shares were sold and at what price?

The officer sold 549 shares of Lexeo common stock at a weighted average price of $9.27 per share, with individual trade prices ranging from $9.09 to $9.37.

Why did the Lexeo Therapeutics officer sell shares in this Form 4?

The filing explains that the sale represents a sale to cover tax obligations triggered by the release of restricted stock units (RSUs), rather than a discretionary open‑market sale of the full position.

How many Lexeo Therapeutics (LXEO) shares does the officer own after the transaction?

Following the reported sale, the officer beneficially owns 68,381 shares of Lexeo common stock, which includes 49,607 RSUs.

What are the restricted stock units (RSUs) mentioned in the Lexeo Form 4?

The filing notes that the officer’s holdings include 49,607 RSUs, which are rights to receive Lexeo common shares, typically subject to vesting or other conditions.

Can investors get detailed pricing for the Lexeo insider sale trades?

Yes. The officer undertakes to provide full information on the number of shares sold at each separate sale price upon request by the SEC staff, Lexeo Therapeutics, or any security holder.